On This Page

Filter

These are the filters currently being used to limit the search results. Click on the
icon to remove the filter.

tabling member › label

Biography information for Liz Kendall

answer › answering member › label

Biography information for George Freeman

Sort by

This list shows the properties that you can sort by. Click on to sort in ascending order and to sort in descending order. The properties that you're currently sorting by are
shown at the top of the list. Click on to remove a sort and or to reverse the current sort order. Click on the icon to remove all the sorting. Note that sorting can significantly slow down the
loading of the page.

View

Choose what information you want to view about each item. There are some pre-defined
views, but starred properties are always present no matter what the view. You can
star properties by clicking on the icon. The currently starred icons have a icon; clicking on it will unstar the property.

<p>The following table shows estimated expenditure on research on asthma, motor neurone
disease (MND) and osteoporosis by the Medical Research Council, other Research Councils
and Innovate UK, and by the National Institute for Health (NIHR) through its research
programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p>
</p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td
colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del
class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del
class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del
class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del
class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del
class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other
Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National
Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del
class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del
class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del
class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del
class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del
class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td
colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other
Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National
Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td
colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other
Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National
Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p>
</p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution
and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p>
</p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the
figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these
diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating
to development of new drugs for asthma, MND and osteroporosis occurs primarily through
NIHR research infrastructure including the CRN and cannot be disaggregated from total
expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the
development of new drugs for asthma, MND or osteoporosis is not available.</p><p>
</p>

To ask the Secretary of State for Health, how much from the public purse has been
spent on the development of new drugs to prevent or treat symptoms of motore neurone
disease in each of the last five years.

<p>The following table shows estimated expenditure on research on asthma, motor neurone
disease (MND) and osteoporosis by the Medical Research Council, other Research Councils
and Innovate UK, and by the National Institute for Health (NIHR) through its research
programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p>
</p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td
colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del
class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del
class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del
class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del
class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del
class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other
Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National
Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del
class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del
class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del
class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del
class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del
class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td
colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other
Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National
Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td
colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other
Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National
Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p>
</p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution
and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p>
</p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the
figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these
diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating
to development of new drugs for asthma, MND and osteroporosis occurs primarily through
NIHR research infrastructure including the CRN and cannot be disaggregated from total
expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the
development of new drugs for asthma, MND or osteoporosis is not available.</p><p>
</p>

<p>The following table shows estimated expenditure on research on asthma, motor neurone
disease (MND) and osteoporosis by the Medical Research Council, other Research Councils
and Innovate UK, and by the National Institute for Health (NIHR) through its research
programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p>
</p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td
colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del
class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del
class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del
class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del
class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del
class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other
Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National
Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del
class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del
class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del
class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del
class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del
class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td
colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other
Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National
Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td
colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other
Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National
Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p>
</p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution
and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p>
</p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the
figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these
diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating
to development of new drugs for asthma, MND and osteroporosis occurs primarily through
NIHR research infrastructure including the CRN and cannot be disaggregated from total
expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the
development of new drugs for asthma, MND or osteoporosis is not available.</p><p>
</p>

<p>The following table shows estimated expenditure on research on asthma, motor neurone
disease (MND) and osteoporosis by the Medical Research Council, other Research Councils
and Innovate UK, and by the National Institute for Health (NIHR) through its research
programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p>
</p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td
colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del
class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del
class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del
class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del
class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del
class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other
Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National
Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del
class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del
class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del
class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del
class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del
class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td
colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other
Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National
Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td
colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other
Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National
Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p>
</p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution
and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p>
</p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the
figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these
diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating
to development of new drugs for asthma, MND and osteroporosis occurs primarily through
NIHR research infrastructure including the CRN and cannot be disaggregated from total
expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the
development of new drugs for asthma, MND or osteoporosis is not available.</p><p>
</p>

<p>The following table shows estimated expenditure on research on asthma, motor neurone
disease (MND) and osteoporosis by the Medical Research Council, other Research Councils
and Innovate UK, and by the National Institute for Health (NIHR) through its research
programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p>
</p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td
colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del
class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del
class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del
class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del
class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del
class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other
Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National
Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del
class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del
class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del
class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del
class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del
class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td
colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other
Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National
Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td
colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other
Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National
Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p>
</p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution
and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p>
</p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the
figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these
diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating
to development of new drugs for asthma, MND and osteroporosis occurs primarily through
NIHR research infrastructure including the CRN and cannot be disaggregated from total
expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the
development of new drugs for asthma, MND or osteoporosis is not available.</p><p>
</p>

<p>The following table shows estimated expenditure on research on asthma, motor neurone
disease (MND) and osteoporosis by the Medical Research Council, other Research Councils
and Innovate UK, and by the National Institute for Health (NIHR) through its research
programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p>
</p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td
colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del
class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del
class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del
class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del
class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del
class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other
Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National
Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del
class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del
class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del
class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del
class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del
class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td
colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other
Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National
Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td
colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other
Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National
Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p>
</p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution
and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p>
</p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the
figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these
diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating
to development of new drugs for asthma, MND and osteroporosis occurs primarily through
NIHR research infrastructure including the CRN and cannot be disaggregated from total
expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the
development of new drugs for asthma, MND or osteoporosis is not available.</p><p>
</p>

<p>Information on National Health Service expenditure on drugs for the treatment of
osteoporosis in primary and secondary care is in the table.</p><p> </p><p> </p><p>
</p><p>Drugs for the treatment of osteoporosis have been defined as those included
in the following British National Formulary sections:</p><p> </p><p>6.6 Drugs affecting
bone metabolism</p><p> </p><p>9.5.1.1 Calcium supplements</p><p> </p><p>9.6 Vitamins
(colecalciferol and ergocalciferol only)</p><p> </p><p><strong> </strong></p><p> </p><table><tbody><tr><td
colspan="11"><p>Cost of drugs for the treatment of osteoporosis, England<sup>1</sup></p></td></tr><tr><td><p>Drug
Name<sup>2</sup></p></td><td colspan="5"><p>Primary Care</p><p>(£ million)</p></td><td
colspan="5"><p>Secondary Care</p><p>(£ million)</p></td></tr><tr><td><p>Year</p></td><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td><td><p>2013</p></td><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td><td><p>2013</p></td></tr><tr><td><p>Alendronic
Acid</p></td><td><p>14.0</p></td><td><p>12.4</p></td><td><p>10.8</p></td><td><p>9.7</p></td><td><p>8.9</p></td><td><p>0.8</p></td><td><p>0.6</p></td><td><p>0.5</p></td><td><p>0.5</p></td><td><p>0.4</p></td></tr><tr><td><p>Alendronic
Acid and Colecalciferol</p></td><td><p>1.4</p></td><td><p>1.2</p></td><td><p>0.9</p></td><td><p>0.7</p></td><td><p>0.6</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Calcitonin
(Salmon)</p></td><td><p>0.3</p></td><td><p>0.3</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.1</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td></tr><tr><td><p>Calcium</p></td><td><p>4.2</p></td><td><p>4.7</p></td><td><p>4.5</p></td><td><p>3.7</p></td><td><p>3.3</p></td><td><p>0.9</p></td><td><p>0.9</p></td><td><p>0.9</p></td><td><p>0.9</p></td><td><p>0.9</p></td></tr><tr><td><p>Calcium
and Colecalciferol</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>2.2</p></td><td><p>2.2</p></td><td><p>2.1</p></td><td><p>2.2</p></td><td><p>2.3</p></td></tr><tr><td><p>Clodronic
Acid</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>2.9</p></td><td><p>2.4</p></td><td><p>1.6</p></td><td><p>1.2</p></td><td><p>0.9</p></td></tr><tr><td><p>Colecalciferol</p></td><td><p>42.4</p></td><td><p>48.3</p></td><td><p>58.5</p></td><td><p>67.6</p></td><td><p>75.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.4</p></td><td><p>1.2</p></td></tr><tr><td><p>Denosumab</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.2</p></td><td><p>0.8</p></td><td><p>1.9</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.9</p></td><td><p>2.3</p></td><td><p>9.9</p></td></tr><tr><td><p>Disodium
Etidronate</p></td><td><p>1.3</p></td><td><p>1.0</p></td><td><p>0.8</p></td><td><p>0.6</p></td><td><p>0.3</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Ergocalciferol</p></td><td><p>4.3</p></td><td><p>7.8</p></td><td><p>8.0</p></td><td><p>7.0</p></td><td><p>6.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.2</p></td><td><p>0.3</p></td></tr><tr><td><p>Ibandronic
Acid</p></td><td><p>12.1</p></td><td><p>12.1</p></td><td><p>11.4</p></td><td><p>10.6</p></td><td><p>4.7</p></td><td><p>2.1</p></td><td><p>2.0</p></td><td><p>1.8</p></td><td><p>1.5</p></td><td><p>0.9</p></td></tr><tr><td><p>Pamidronic
Acid</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>9.6</p></td><td><p>9.1</p></td><td><p>9.4</p></td><td><p>9.4</p></td><td><p>8.7</p></td></tr><tr><td><p>Risedronate
Sodium and Risedronate Acid</p></td><td><p>27.9</p></td><td><p>22.9</p></td><td><p>11.6</p></td><td><p>2.4</p></td><td><p>2.0</p></td><td><p>0.8</p></td><td><p>0.6</p></td><td><p>0.3</p></td><td><p>0.1</p></td><td><p>0.1</p></td></tr><tr><td><p>Sodium
Clodronate</p></td><td><p>7.8</p></td><td><p>7.2</p></td><td><p>6.3</p></td><td><p>5.5</p></td><td><p>4.3</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Strontium
Ranelate</p></td><td><p>7.0</p></td><td><p>7.8</p></td><td><p>9.0</p></td><td><p>9.2</p></td><td><p>7.3</p></td><td><p>0.6</p></td><td><p>0.6</p></td><td><p>0.6</p></td><td><p>0.5</p></td><td><p>0.2</p></td></tr><tr><td><p>Teriparatide</p></td><td><p>0.3</p></td><td><p>0.4</p></td><td><p>0.4</p></td><td><p>0.5</p></td><td><p>0.6</p></td><td><p>2.7</p></td><td><p>2.8</p></td><td><p>2.7</p></td><td><p>3.1</p></td><td><p>3.2</p></td></tr><tr><td><p>Zoledronic
Acid</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>16.7</p></td><td><p>18.0</p></td><td><p>20.9</p></td><td><p>23.7</p></td><td><p>25.7</p></td></tr><tr><td><p>Other
Calcium Supplement Preps</p></td><td><p>0.5</p></td><td><p>0.6</p></td><td><p>0.6</p></td><td><p>0.5</p></td><td><p>0.5</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Other
drugs<sup>3</sup></p></td><td><p>0.2</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.2</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.0</p></td></tr><tr><td><p>TOTAL</p></td><td><p>123.8</p></td><td><p>126.8</p></td><td><p>123.4</p></td><td><p>119.1</p></td><td><p>115.4</p></td><td><p>39.6</p></td><td><p>39.6</p></td><td><p>42.3</p></td><td><p>46.2</p></td><td><p>55.0</p></td></tr></tbody></table><p>
</p><p><sup>1 </sup>Cost of drugs at NHS list price. It does not take account of discounts,
dispensing costs, fees or prescription charges income. Totals may not add up due to
rounding.</p><p> </p><p><sup>2</sup> The patent for some of these drugs may have expired
during this period.</p><p> </p><p><sup>3</sup> “Other drugs” includes Calcium and
Colecalciferol and Ergocalciferol, Calcium and Etidronic Acid, Calcium and Risedronic
and Colecalciferol, Disodium Pamidronate, Ergocalciferol and Calcium, Etidronic Acid,
Hydroxyapatite, Parathyroid Hormone, Salcatonin, Tiludronic Acid, other Bisphosphonate
and other Preparations.</p><p> </p><p> </p><p> </p><p><em>Source: </em></p><p> </p><p>Prescription
Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary
care)</p><p> </p><p>Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary
care)</p><p> </p><p> </p><p> </p><p>Since some drugs are prescribed to treat more
than one condition and as the condition for which a drug is prescribed is not collected,
it is not possible to separate the different conditions for which a drug may have
been prescribed. The information provided may therefore include costs from the prescribing
of these drugs for conditions other than for osteoporosis.</p><p> </p><p> </p><p>
</p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p>
</p><p><strong> </strong></p><p> </p>

<p>Information on National Health Service expenditure on drugs for the treatment of
motor neurone disease in primary and secondary care is in the table.</p><p> </p><p><strong>
</strong></p><p> </p><p>Riluzole is the only drug defined in the British National
Formulary as being used for the treatment of motor neurone disease</p><p> </p><p>
</p><p> </p><table><tbody><tr><td colspan="3"><p>Cost of riluzole, England<sup>1</sup></p></td></tr><tr><td><p>Year</p></td><td><p>Primary
Care</p><p>(£ million)</p></td><td><p>Secondary Care</p><p>(£ million)</p></td></tr><tr><td><p>2009</p></td><td><p>3.8</p></td><td><p>1.2</p></td></tr><tr><td><p>2010</p></td><td><p>4.9</p></td><td><p>1.4</p></td></tr><tr><td><p>2011</p></td><td><p>5.5</p></td><td><p>1.4</p></td></tr><tr><td><p>2012</p></td><td><p>5.8</p></td><td><p>1.5</p></td></tr><tr><td><p>2013<sup>2</sup></p></td><td><p>2.3</p></td><td><p>1.0</p></td></tr></tbody></table><p>
</p><p><sup>1</sup> Cost of drugs at NHS list price. It does not take account of discounts,
dispensing costs, fees or prescription charges income.</p><p> </p><p><sup>2 </sup>The
patent for riluzole expired in the first quarter of 2013.</p><p> </p><p><em>Source:
</em></p><p> </p><p>Prescription Cost Analysis (PCA) provided by the Health and Social
Care Information Centre (primary care)</p><p> </p><p>Hospital Pharmacy Audit Index
(HPAI) provided by IMS Health (secondary care)</p><p> </p><p> </p><p> </p><p>Since
a drug could be prescribed to treat more than one condition and as the condition for
which a drug is prescribed is not collected, it is not possible to separate the different
conditions for which it may have been prescribed. The information provided may therefore
include costs from the prescribing of the drug for conditions other than for motor
neurone disease.</p><p> </p>

<p>Information on National Health Service expenditure on drugs for the treatment of
asthma in primary and secondary care is in the table.</p><p> </p><p><strong> </strong></p><p>
</p><p>Drugs for the treatment of osteoporosis have been defined as those included
in the following British National Formulary sections:</p><p> </p><p>3.1.1 Adrenoceptor
agonists</p><p> </p><p>3.1.2 Antimuscarinic bronchodilators</p><p> </p><p>3.1.3 Theophylline</p><p>
</p><p>3.2 Corticosteroids</p><p> </p><p>3.3.1 Cromoglicate and related therapy</p><p>
</p><p>3.3.2 Leukotriene receptor antagonists</p><p> </p><p>3.4.2 Allergen immunotherapy
(omalizumab only)</p><p> </p><p> </p><p> </p><table><tbody><tr><td colspan="11"><p>Cost
of drugs for the treatment of asthma, England<sup>1</sup></p></td></tr><tr><td rowspan="2"><p>Drug
name</p></td><td colspan="5"><p>Primary Care (£ millions)</p></td><td colspan="5"><p>Secondary
Care (£ millions)</p></td></tr><tr><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td><td><p>2013</p></td><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td><td><p>2013</p></td></tr><tr><td><p>Aclidinium
Bromide</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>0.02</p></td><td><p>1.62</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>0.00</p></td><td><p>0.03</p></td></tr><tr><td><p>Aminophylline</p></td><td><p>1.25</p></td><td><p>1.18</p></td><td><p>1.12</p></td><td><p>1.08</p></td><td><p>1.05</p></td><td><p>0.30</p></td><td><p>0.29</p></td><td><p>0.21</p></td><td><p>0.23</p></td><td><p>0.22</p></td></tr><tr><td><p>Beclometasone
Dipropionate</p></td><td><p>84.26</p></td><td><p>87.72</p></td><td><p>90.30</p></td><td><p>97.56</p></td><td><p>102.39</p></td><td><p>1.62</p></td><td><p>1.53</p></td><td><p>1.41</p></td><td><p>1.49</p></td><td><p>1.42</p></td></tr><tr><td><p>Budesonide</p></td><td><p>140.35</p></td><td><p>149.03</p></td><td><p>158.82</p></td><td><p>169.14</p></td><td><p>177.00</p></td><td><p>1.29</p></td><td><p>1.14</p></td><td><p>1.14</p></td><td><p>1.27</p></td><td><p>1.41</p></td></tr><tr><td><p>Budesonide/
Formoterol</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>2.75</p></td><td><p>2.94</p></td><td><p>2.89</p></td><td><p>3.10</p></td><td><p>3.29</p></td></tr><tr><td><p>Ciclesonide</p></td><td><p>0.84</p></td><td><p>0.95</p></td><td><p>1.03</p></td><td><p>1.12</p></td><td><p>1.25</p></td><td><p>0.01</p></td><td><p>0.02</p></td><td><p>0.02</p></td><td><p>0.02</p></td><td><p>0.03</p></td></tr><tr><td><p>Fluticasone</p></td><td><p>366.24</p></td><td><p>380.56</p></td><td><p>387.89</p></td><td><p>392.95</p></td><td><p>396.10</p></td><td><p>1.00</p></td><td><p>0.93</p></td><td><p>0.91</p></td><td><p>1.00</p></td><td><p>0.99</p></td></tr><tr><td><p>Fluticasone/
Salmeterol</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>11.46</p></td><td><p>11.56</p></td><td><p>10.69</p></td><td><p>10.82</p></td><td><p>10.48</p></td></tr><tr><td><p>Formoterol
Fumarate</p></td><td><p>5.18</p></td><td><p>4.87</p></td><td><p>4.68</p></td><td><p>4.85</p></td><td><p>4.93</p></td><td><p>0.10</p></td><td><p>0.08</p></td><td><p>0.07</p></td><td><p>0.06</p></td><td><p>0.06</p></td></tr><tr><td><p>Glycopyrronium
Bromide</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>0.01</p></td><td><p>2.30</p></td><td><p>0.58</p></td><td><p>0.62</p></td><td><p>0.70</p></td><td><p>0.79</p></td><td><p>1.00</p></td></tr><tr><td><p>Indacaterol
Maleate</p></td><td><p>-</p></td><td><p>0.04</p></td><td><p>0.30</p></td><td><p>0.92</p></td><td><p>1.47</p></td><td><p>-</p></td><td><p>0.00</p></td><td><p>0.00</p></td><td><p>0.02</p></td><td><p>0.04</p></td></tr><tr><td><p>Ipratropium
Bromide</p></td><td><p>16.15</p></td><td><p>15.02</p></td><td><p>13.74</p></td><td><p>10.32</p></td><td><p>8.61</p></td><td><p>2.74</p></td><td><p>2.84</p></td><td><p>2.59</p></td><td><p>2.65</p></td><td><p>2.70</p></td></tr><tr><td><p>Mometasone
Furoate</p></td><td><p>0.36</p></td><td><p>0.31</p></td><td><p>0.26</p></td><td><p>0.23</p></td><td><p>0.21</p></td><td><p>0.76</p></td><td><p>0.71</p></td><td><p>0.61</p></td><td><p>0.63</p></td><td><p>0.67</p></td></tr><tr><td><p>Montelukast</p></td><td><p>38.91</p></td><td><p>43.01</p></td><td><p>46.96</p></td><td><p>51.71</p></td><td><p>31.31</p></td><td><p>0.98</p></td><td><p>1.02</p></td><td><p>1.03</p></td><td><p>1.16</p></td><td><p>0.81</p></td></tr><tr><td><p>Omalizumab</p></td><td><p>0.00</p></td><td><p>0.01</p></td><td><p>0.03</p></td><td><p>0.15</p></td><td><p>0.12</p></td><td><p>5.97</p></td><td><p>9.22</p></td><td><p>12.16</p></td><td><p>14.65</p></td><td><p>17.86</p></td></tr><tr><td><p>Salbutamol</p></td><td><p>83.15</p></td><td><p>82.64</p></td><td><p>60.58</p></td><td><p>60.37</p></td><td><p>59.95</p></td><td><p>3.78</p></td><td><p>3.77</p></td><td><p>3.36</p></td><td><p>3.38</p></td><td><p>3.29</p></td></tr><tr><td><p>Salmeterol</p></td><td><p>48.80</p></td><td><p>45.16</p></td><td><p>41.87</p></td><td><p>36.72</p></td><td><p>34.04</p></td><td><p>0.87</p></td><td><p>0.74</p></td><td><p>0.59</p></td><td><p>0.53</p></td><td><p>0.47</p></td></tr><tr><td><p>Terbutaline
Sulphate</p></td><td><p>8.61</p></td><td><p>8.20</p></td><td><p>7.61</p></td><td><p>7.43</p></td><td><p>7.18</p></td><td><p>0.18</p></td><td><p>0.16</p></td><td><p>0.14</p></td><td><p>0.14</p></td><td><p>0.15</p></td></tr><tr><td><p>Theophylline</p></td><td><p>2.18</p></td><td><p>2.17</p></td><td><p>2.15</p></td><td><p>2.22</p></td><td><p>2.26</p></td><td><p>0.12</p></td><td><p>0.11</p></td><td><p>0.11</p></td><td><p>0.11</p></td><td><p>0.11</p></td></tr><tr><td><p>Tiotropium</p></td><td><p>113.61</p></td><td><p>129.98</p></td><td><p>149.81</p></td><td><p>169.35</p></td><td><p>185.24</p></td><td><p>5.69</p></td><td><p>6.03</p></td><td><p>6.22</p></td><td><p>6.64</p></td><td><p>6.87</p></td></tr><tr><td><p>Zafirlukast</p></td><td><p>0.79</p></td><td><p>0.71</p></td><td><p>0.71</p></td><td><p>0.70</p></td><td><p>0.69</p></td><td><p>0.01</p></td><td><p>0.01</p></td><td><p>0.01</p></td><td><p>0.01</p></td><td><p>0.01</p></td></tr><tr><td><p>Other
drugs<sup>2</sup></p></td><td><p>0.90</p></td><td><p>0.79</p></td><td><p>0.66</p></td><td><p>0.62</p></td><td><p>0.60</p></td><td><p>0.04</p></td><td><p>0.07</p></td><td><p>0.15</p></td><td><p>0.26</p></td><td><p>0.46</p></td></tr><tr><td><p>Total</p></td><td><p>911.6</p></td><td><p>952.3</p></td><td><p>968.5</p></td><td><p>1,007.5</p></td><td><p>1,018.3</p></td><td><p>40.3</p></td><td><p>43.8</p></td><td><p>45.0</p></td><td><p>49.0</p></td><td><p>52.4</p></td></tr></tbody></table><p>
</p><p> </p><p> </p><p><sup>1 </sup>Cost of drugs at NHS list price not taking account
of discounts, dispensing costs, fees or prescription charges income. Totals may not
add up due to rounding.</p><p> </p><p><sup>2</sup> Other drugs include Azelastine/Fluticasone,
Bambuterol Hydrochloride, Beclometasone/ Formoterol, Cromoglicic Acid, Fenoterol Hydrobromide,
Fenoterol/Ipratropium Bromide, Fluticasone/ Formoterol, Nedocromil Sodium, Orciprenaline
Sulfate and Sodium Cromoglicate.</p><p> </p><p>Source:</p><p> </p><p>Prescription
Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary
care)</p><p> </p><p>Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary
care)</p><p> </p><p> </p><p> </p><p>Since some drugs are prescribed to treat more
than one condition and as the condition for which a drug is prescribed is not collected,
it is not possible to separate the different conditions for which a drug may have
been prescribed. The information provided may therefore include costs from the prescribing
of these drugs for conditions other than for asthma.</p><p> </p>

<p>Information is not collected centrally on the numbers of prescriptions issued,
the number of people prescribed medicines or the medical condition being treated.
However, information is available on the number of prescription items dispensed in
the community in England. This is attached.</p><p> </p>